Super-infections: does the humankind have weapons to fight?


INTRODUCTION. The resistance of microorganisms to anti-infective drugs is recognized by WHO as a global threat to humankind: more than 700,000 people die every year from infectious diseases caused by drug-resistant agents, and this amount is significantly underestimated due to the low level of diagnosis. In the absence of effective steps that can reduce the rate of formation of resistance, by 2050 this figure will increase to 10 million people.

MATERIALS AND METHODS. Retrospective analysis of literature sources – recommendations, resolutions of the WHO and the UN, scientific articles, analytical reports and statistical data.

RESULTS. An overview of the data showed that the resistance of microorganisms to anti-infective drugs is a natural process, but the rate of its formation to existing medicines is threatening and exceeds the possibility of introducing new drugs, which poses a threat to all humanity, not only in the form of a rapid increase in the mortality rate from resistant infections, but also significantly limits the possibility to apply high-tech treatment methods that require anti-infective support.

CONCLUSIONS. Social awareness, motivation, commitment to responsible action, strict rules for the use of anti-infective agents and control of their turnover, the introduction of best management practices and the development of behavioral changes in all industry sectors, the use of modern technology that will help patients (for example, to timely recall drugs) can become important tools to overcome the burden of super-infections in Ukraine and in the world.

Keywords: super-infection, resistance, anti-infective drugs.


WHO GAP AMR Newsletter No.32 November 2017


WHO, Tuberculosis Factsheet, Online, Available at:

factsheets/fs104/en/ Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance – the need for global solutions, The Lancet Infectious Diseases. 2013; 13: p.1057-98

Davies SC. Annual report of the Chief Medical Officer 2011: Volume 2. London: UK Department of Health. 2013

Boucher HW, Talbot GH, Bradley JS, Edwards JR Jr, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clinical Infectious Diseases. 2009; 41: 1-12

Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015 (, accessed 22 March 2018

WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals, version 1.1 WHO/EMP/IAU/2018.01

No Time to Wait: Securing the future from drug-resistant infections. Report to the Secretary-General of the United Nations

Levy SB, Marshall B: Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004; 10:122–129.

Zaman SB, Hossain N: Universal Health Coverage: A burning need for developing countries . J Med Res and Innov. 2017; 1:18–20.

Woodhead M, Finch R: Public education—a progress report . J Antimicrob Chemother. 2007; 60:53–55.

Zaman SB, Hossain N, Ahammed S, et al.: Contexts and opportunities of e-health technology in medical care. J Med Res and Innov. 2017; 1:1–4.

How to Cite
Feshchenko, Y., & Gumeniuk, M. (2019). Super-infections: does the humankind have weapons to fight?. Infusion & Chemotherapy, (1), 3-8.

Author Biographies

Y.I. Feshchenko, SO "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine”, Kyiv, Ukraine

Yurii I. Feshchenko
President of Civic Union “Communicable diseases intensive care association”.
Academician of NAMS of Ukraine, professor
10, M. Amosova str., 03038, Kyiv, Ukraine

M.I. Gumeniuk, SO "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky NAMS of Ukraine”, Kyiv, Ukraine

Gumeniuk Mykola
Leading Researcher, Department of Technologies of Treatment of Nonspecific Lung Diseases
Doctor of medicine.
10, M. Amosova str., 03038, Kyiv, Ukraine